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A B S T R A C T
Background
The burden of shigellosis is greatest in resource-poor countries. Although this diarrheal
disease has been thought to cause considerable morbidity and mortality in excess of 1,000,000
deaths globally per year, little recent data are available to guide intervention strategies in Asia.
We conducted a prospective, population-based study in six Asian countries to gain a better
understanding of the current disease burden, clinical manifestations, and microbiology of
shigellosis in Asia.
Methods and Findings
Over 600,000 persons of all ages residing in Bangladesh, China, Pakistan, Indonesia, Vietnam,
and Thailand were included in the surveillance. Shigella was isolated from 2,927 (5%) of 56,958
diarrhoea episodes detected between 2000 and 2004. The overall incidence of treated
shigellosis was 2.1 episodes per 1,000 residents per year in all ages and 13.2/1,000/y in children
under 60 months old. Shigellosis incidence increased after age 40 years. S. flexneri was the most
frequently isolated Shigella species (1,976/2,927 [68%]) in all sites except in Thailand, where S.
sonnei was most frequently detected (124/146 [85%]). S. flexneri serotypes were highly
heterogeneous in their distribution from site to site, and even from year to year. PCR detected
ipaH, the gene encoding invasion plasmid antigen H in 33% of a sample of culture-negative
stool specimens. The majority of S. flexneri isolates in each site were resistant to amoxicillin and
cotrimoxazole. Ciprofloxacin-resistant S. flexneri isolates were identified in China (18/305 [6%]),
Pakistan (8/242 [3%]), and Vietnam (5/282 [2%]).
Conclusions
Shigella appears to be more ubiquitous in Asian impoverished populations than previously
thought, and antibiotic-resistant strains of different species and serotypes have emerged.
Focusing on prevention of shigellosis could exert an immediate benefit first by substantially
reducing the overall diarrhoea burden in the region and second by preventing the spread of
panresistant Shigella strains. The heterogeneous distribution of Shigella species and serotypes
suggest that multivalent or cross-protective Shigella vaccines will be needed to prevent
shigellosis in Asia.
The Editors’ Summary of this article follows the references.
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Introduction
The burden of shigellosis is greatest in resource-poor
countries where the disease may cause as many as 167 million
episodes of diarrhea and over a million deaths annually [1].
Previously efﬁcacious drugs such as sulphonamides, tetracy-
cline, ampicillin, and trimethoprim-sulfamethoxazole have
become largely ineffective against prevalent Shigella strains.
The recently reported emergence of ciproﬂoxacin resistance
further narrows the choice of effective antimicrobials [2–4].
S. ﬂexneri species are known to have 15 serotypes and
subtypes, S. dysenteriae 13 serotypes, S. boydii 18 serotypes, and
S. sonnei a single serotype. Several vaccine candidates are
under development [5–10], but these may need to be tailored
according to prevalent species and serotypes, since only type-
speciﬁc immunity has been demonstrated in humans [11–13]
and cross-serotype protection is controversial [14]. A detailed
understanding of the epidemiology of shigellosis is essential
for the rational development of potential vaccine candidates
to control shigellosis.
Because of the lack of recent, reliable data on shigellosis,
especially from nonindustrialized countries, we conducted a
prospective, multicentre, population-based study of the
burden and patterns of shigellosis in six developing countries
of Asia.
Methods
To allow pooling of data and comparisons across study
sites, standardized epidemiologic, clinical, and laboratory
methods were employed. Prior to the project start, methods
were agreed upon by the principal investigators during
workshops. The studies were monitored by epidemiologic and
laboratory coordinators during regular visits to the study
sites. A full description of healthcare systems and healthcare
utilization patterns in the study sites [15–20] as well as
epidemiologic and microbiologic methodology in the study
sites in Indonesia [21], China [22], and Thailand [23] have
been presented elsewhere.
Study Sites and Population
Surveillance was conducted at study sites in six developing
countries of Asia: three rural or semirural areas (China,
Vietnam, and Thailand) and three urban slums (Bangladesh,
Pakistan, and Indonesia) (Table 1). The population size in each
study site was estimated through existing, recent census data
(China, Thailand, Indonesia) or a census specially conducted
for the purpose of the study (Bangladesh, Pakistan, Vietnam).
The research site in China was in Hebei Province,
approximately 270 km south of Beijing. The catchment area
consisted of 29 villages in four rural townships in Zhengding
County with a total population of 75,630 in 2000, of which
2,997 (4%) were children under age 60 mo. About 80% of the
study population were agricultural workers. Surveillance was
conducted in 101 village clinics and four township hospitals.
The Thailand study area was in Kaengkhoi District,
Saraburi Province, approximately 100 km north of Bangkok.
The area includes a small city surrounded by rural villages
that depend on agriculture for income. In 2001 80,141 people
lived in the catchment area, including 5,686 (7%) children
under age 60 mo. Surveillance was conducted in 20
community health centres and the district hospital.
In Indonesia, two adjacent districts (kecamatans) in North
Jakarta, Tanjung Priok, and Koja, formed the study area.
Many homes are temporary structures without running water,
and more than one-third of households have no access to tap
water. The area is prone to ﬂooding during the rainy season.
The main occupations include harbour labour, small busi-
ness, and clerical work. In 2000 the population in the
catchment area was 160,257, of whom 15,741 (10%) were
under age 60 mo. Surveillance was conducted in eight public
health care centres (puskesmas) and two hospitals (the
Infectious Disease Hospital and Koja Hospital).
In Vietnam, the study was conducted in the coastal city of
Nha Trang, the provincial capital of Khanh Hoa Province in
the central part of the country. The population in the
catchment area was 200,410, of which 13,970 (7%) were under
age 60 mo. This population is mostly employed in ﬁsheries,
agriculture, and tourism. Surveillance was conducted in
community health centres of 16 communes, in four poly-
clinics, and in the general hospital.
In Pakistan the research site included four low-income
communities. Rehri Goth, a suburban ﬁshing village, and
Sherpao Colony, where most people earn a living as labourers,
are both southeast of Karachi. Hijrat Colony and Sultanabad,
two contiguous urban slums, are near the business centre and
port of Karachi. The catchment area in 2002 had a population
of 59,584, of which 8,381 (14%) were children under age 60
mo. In each of the four communities a treatment centre was
established for the purpose of surveillance.
In Bangladesh the study catchment area was in Kamlapur, a
densely populated settlement of rural immigrants in the
southeastern sector of Dhaka city. The population in the
catchment area was 29,309, of which 3,741 (13%) were
children under age 60 mo. The rapid growth of the settlement
has resulted in a mixture of permanent structures and
temporary squatter dwellings. The most common occupa-
tions are trading, clerical work, and rickshaw puller. One
central treatment centre was used for surveillance.
Project Design
Before and during surveillance, information campaigns
were conducted to encourage all residents in each of the
catchment areas to visit a participating health care centre
and provider for all diarrhoea episodes. Individuals of all ages
presenting with diarrhoea or dysentery were enrolled in the
study. The clinical history and physical ﬁndings of each
patient were documented on standardized case report forms.
A rectal swab or bulk stool was obtained from each patient
who provided verbal informed consent. The rectal or bulk
stool swabs were inserted into 1.5 ml of buffered glycerol
saline or Cary Blair medium, refrigerated until collection by a
courier, transported in a cool box to the central laboratory by
motorcycle or car, and plated on the day of collection.
Participants received treatment according to national guide-
lines.
Definitions
Diarrhoea was deﬁned as three or more loose bowel
movements during a 24-h period, dysentery as one or more
loose bowel movements with visible blood. A diarrhoeal
episode was deﬁned as new if the diarrhoea deﬁnition was
met after three or more days free of diarrhoea or dysentery
[24]. A shigellosis episode was deﬁned as a diarrhea episode
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during which a faecal specimen was obtained from which any
Shigella species was isolated. An episode of persistent diarrhea
was deﬁned as an episode of diarrhea lasting for 14 d or more.
Laboratory Procedures
The swabs were inoculated in MacConkey agar and
Salmonella-Shigella agar. After overnight incubation at 37 8C,
the MacConkey agar and Salmonella-Shigella agar plates were
checked for nonlactose-fermenting colonies. Three colonies
characteristically resembling Shigella were differentiated from
other nonlactose-fermenting enteropathogens by inoculating
into Kligler’s iron agar for typical reaction, mannitol fermen-
tation, citrate utilization, urease and indole production, and
lysine decarboxylation. After incubation for 18–24 h at 37 8C,
the test media were read for characteristic Shigella reactions.
Serologic identiﬁcation was performed by slide agglutina-
tion with polyvalent somatic (O) antigen grouping sera,
followed by testing with monovalent antisera for speciﬁc
serotype identiﬁcation (antisera from Denka Seiken, Japan,
were used in all sites). In cases where no agglutination
occurred with live bacteria, the test was repeated with boiled
suspensions of bacteria. S. ﬂexneri isolates that were not
typeable with commercial antisera were evaluated at Centre
for Health and Population Research, Dhaka, Bangladesh
using a panel of monoclonal antibodies speciﬁc for S. ﬂexneri
group and type factor antigen [25–28].
Antimicrobial susceptibility testing of Shigella isolates
against ampicillin, cotrimoxazole, nalidixic acid, and cipro-
ﬂoxacin was performed by disk diffusion following stand-
ardized National Committee for Clinical Laboratory
Standards methods. Specimens were processed in local
laboratories (Bangladesh: Centre for Health and Population
Research, Dhaka; China: Preventive Health Laboratory,
Zhengding; Pakistan: Aga Khan University, Karachi; Indone-
sia: United States Navy Medical Research Unit 2, Jakarta;
Vietnam: Institute Pasteur, Nha Trang; and Thailand:
Kaengkhoi Hospital, Saraburi).
The species, serotypes, subtypes, and antimicrobial resist-
ance patterns of a sample of Shigella strains from the study
sites in Vietnam, Bangladesh, and Pakistan were conﬁrmed at
the United States Armed Forces Research Institute for
Medical Sciences, Bangkok during the initial months of each
study. All Shigella isolates from the site in Thailand were
conﬁrmed at the World Health Organization National
Salmonella and Shigella Centre, Ministry of Public Health,
Nonthaburi, and all isolates from the study site in China were
conﬁrmed in Fudan University, Shanghai.
Real-Time PCR
PCR can be used to amplify the gene coding for the
invasion plasmid antigen H (ipaH), a gene nearly exclusively
derived from the four Shigella spp. in Asia. The only
Table 1. Study Population, Disease Episodes, and Incidence at Six Study Sites
Age Group Characteristic China Thailand Indonesia Vietnam Pakistan Bangladesh Total
All ages Study site Zhengding Saraburi North Jakarta Nha Trang Karachi Dhaka –
Total population 75,630 80,141 160,257 200,410 59,584 29,309 605,331
Surveillance period 1/2002–
12/2002
5/2000–
4/2003
8/2001–
7/2003
1/2001–
12/2003
1/2002–
12/2003
6/2002–
5/2004
–
Presentations 11,342 8,612 16,872 11,419 10,540 3,481 62,266
Diarrhoea episodes included in analysis
(% of presentations)a
10,104 (89%) 6,536 (76%) 16,225 (96%) 10,258 (90%) 10,371 (98%) 3,464 (100%) 56,958 (91%)
Diarrhoea episodes in which Shigella
spp. isolated (% of included episodes)
330 (3%) 146 (2%) 1,203 (7%) 390 (4%) 394 (4%) 464 (13%) 2,927 (5%)
S. flexneri episodes (% of Shigella
episodes)
305 (92%) 22 (15%) 866 (72%) 282 (72%) 242 (62%) 259 (58%) 1,976 (68%)
S. sonnei episodes (% of Shigella
episodes)
25 (8%) 124 (85%) 277 (23%) 101 (26%) 72 (18%) 53 (10%) 652 (22%)
S. dysenteriae episodes (% of Shigella
episodes)
0 0 21 (2%) 6 (2%) 37 (9%) 46 (9%) 110 (4%)
S. boydii episodes (% of Shigella
episodes)
0 0 39 (3%) 1 (0%) 43 (11%) 106 (23%) 189 (6%)
Shigellosis episodes hospitalized
(% of Shigella episodes)
5 (2%) 2 (1%) 76 (6%) 71 (18%) 0 (0%) NA 154 (6%)
Estimated % of culture-negative
specimens ipaH-PCR positive (95% CI)
52%
(45%–60%)
14%
(9%–19%)
17%
(13%–21%)
38%
(32%–43%)
41%
(35%–47%)
45%
(42%–49%)
33%
(30%–35%)
IR diarrhea, per 100 per year 13.4 2.7 5.1 1.7 8.7 5.9 4.0
IR shigellosis, per 1,000 per year 4.4 0.6 3.8 0.6 3.3 7.9 2.1
Under 5 y Population (% of total) 2,997 (4%) 5,686 (7%) 15,741 (10%) 13,970 (7%) 8,381 (14%) 3,741 (13%) 50,515 (8%)
Diarrhoea episodes 1,851 1,618 10,998 4,820 8,084 2,579 29,950
Diarrhoea episodes in which Shigella
spp. isolated
58 69 584 207 290 345 1,553
Shigellosis episodes hospitalized
(% of Shigella episodes)
2 (3%) 2 (3%) 39 (7%) 44 (21%) 0 (0%) NA 87 (7%)
IR diarrhoea, per 100 per year 61.8 9.5 34.9 11.5 48.2 34.5 25.4
IR shigellosis, per 1,000 per year 19.4 4.0 18.6 4.9 17.3 46.1 13.2
aTo be included in the analysis patients had to have diarrhoea, defined as three or more loose bowel movements within one day or one or more loose bowel movements with visible
blood, and to consent to participate in the study.
IR, incidence rate; NA, not available.
DOI: 10.1371/journal.pmed.0030353.t001
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alternative source of ipaH are enteroinvasive E. coli, an
organism that is exceedingly rare in the Asian region [29].
Studies using ipaH-based PCR have been published from
several Asian countries, including Thailand, Bangladesh, and
more recently, India [30–32]. These studies suggest that ipaH
can be detected in a large percentage of patients with
diarrhoea who are culture-negative for Shigella. It is likely that
ipaH detection rates differ not only between stool specimens
from culture-positive and culture-negative diarrhoea patients
but also between age groups and patients with dysentery and
patients with diarrhoea without visible blood. Stool speci-
mens from diarrhoea patients were therefore classiﬁed into
eight categories as follows: by culture status (Shigella spp.
isolated yes/no), presentation (dysentery/nondysentery), and
age group (under 60 mo, 60 mo and older). Because it was not
feasible to test all culture-negative stool specimens, a sample
of specimens was selected from each of the above categories
at each site.
The sample size required to detect a 95% prevalence of
ipaH within a 95% conﬁdence interval (CI) of 86%–99% was
60, and the sample size required to detect a 35% prevalence
of Shigella DNA within a 95% CI of 26%–43% was 125. If
more specimens had been collected than were required for
testing, samples were randomly selected using a computer
algorithm. 560 specimens each from Vietnam, Pakistan, and
Indonesia were tested. For logistic reasons, a smaller sample
was tested from China (n ¼ 337) and Thailand (n ¼ 320). The
Bangladesh site provided 980 specimens from diarrhoea
patients, of which 39 were culture-conﬁrmed shigellosis cases.
A real-time PCR targeting ipaH was employed to detect
Shigella DNA in faecal specimens [33]. Brieﬂy, the ﬂuorogenic
probe (FAM-CGC CTT TCC GAT ACC GTC TCT GCA-
TAMRA) and its ﬂanking primer pair (forward primer ipaH
U1, 59- CCT TTT CCG CGT TCC TTG A-39; reverse primer
ipaH L1, 59- CGG AAT CCG GAG GTA TTG C-39) were
designed on the basis of ipaH gene sequences.
For real-time PCR detection, faecal swabs were washed in
0.8 ml of PBS, of which 0.5 ml was pipetted into 1.5 ml
microcentrifuge tubes. The tubes were incubated in boiling
water for 30 minutes to lyse bacterial cells. The lysate was
subjected to centrifugation at 10,000 rpm for 1 min. The
lysate was either used directly for real-time PCR or stored at
70 8C. The working cocktail for the detection contained 1 ll
of DNA template, 13 TaqMan buffer A (Applied Biosystems,
Foster City, California, United States), 2 mM MgCl2, 100 nM
each of dNTPs, 200 nM of primers (ipaH-U1 and ipaH-L1), 40
nM of ﬂuorogenic probe, ipaH-P1 (TET-labelled), and 1.25
units of AmpliTaq Gold (Applied Biosystems) in 25 ll of total
reaction volume. The TaqMan assays were conducted using
an ABI 7700 Detection System (Applied Biosystems). The
ampliﬁcation proﬁle consisted of heat activation at 95 8C for
10 min; 40 cycles of denaturation at 95 8C for 30 s; and
annealing, extension, and ﬂuorogenic probe hybridization at
60 8C for 1 min. The assay was considered positive when the
number of cycles to detection was 38 or less. Real-time PCR-
negative samples found to contain inhibitors were further
puriﬁed using Qiagen Stool Kit (Qiagen, Valencia, California,
United States). All PCR assays were conducted at the
Figure 1. Assembly of Cases
* Eligibility criteria: three or more bowel movements per 24 h or at least one loose stool with blood, and consent from patient or parent/guardian.
DOI: 10.1371/journal.pmed.0030353.g001
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USAFRIMS, Bangkok, Thailand, and technicians were blinded
as to the culture status and clinical presentation of the
participants from which the faecal specimens were obtained.
Data Management and Analysis
Data were double entered into a custom data entry
program (FoxPro, Microsoft, Redmond, Washington, United
States) with error- and consistency-check programs. Annual-
ised incidence per thousand population was calculated by
using age-speciﬁc denominators from the baseline census at
each site. The observation periods ranged from 12 to 36 mo at
each site, and we assumed that each person residing in the
study area at the time of the census contributed the
respective months to the denominator. The number of all
age-speciﬁc disease episodes including repeat episodes was
used as the numerator. We calculated 95% CIs for incidence
rates by the Wilson score method [34]. For intergroup
comparisons, we used Chi-square tests for comparison of
categorical variables. For the analysis of continuous variables,
Student’s t-test was used for normally distributed and
Wilcoxon rank sum, and Kruskal-Wallis test for non-normally
distributed data. Rate ratios were used to detect statistically
signiﬁcant differences between incidence rates.
Because the presentations varied by age, species, and site,
adjusted logistic regression models were used to assess
whether symptoms were more frequent in shigellosis
patients compared to diarrhoea patients from whom no
Shigella species were isolated. The models took the presence
of a sign or symptom in each analyzed diarrhoea episode as
the dependent variable and ﬁtted the shigellosis status
(shigellosis or a diarrhoea episode during which no Shigella
spp. could be isolated) and biologically plausible potential
confounders (age and site) as independent variables.
Interactions were tested to estimate the effect of age, site,
and Shigella species on the frequency of the presenting signs
and symptoms. In a secondary analysis, the shigellosis status
was replaced as the independent variable with individual
Shigella species to evaluate the association between individ-
ual species and presentations. The analysis of factors
associated with persistent diarrhoea was conducted in an
analog fashion.
Coefﬁcients of independent variables in the models were
exponentiated to estimate the odds ratio of symptoms
associated with shigellosis status. Standard errors for the
coefﬁcients were used to estimate two-tailed p-values and
associated 95% CIs for the odds ratios. The disproportionate
Figure 2. Overall Shigellosis Incidence by Age Group at Study Sites in Six Asian Countries
Note: Shigellosis incidence in the age group 0–4 y is 13.2/1,000/y.
DOI: 10.1371/journal.pmed.0030353.g002
Figure 3. Clinical Presentation of Shigellosis Episodes
A history of more than one clinical sign and symptom during a single episode is possible.
DOI: 10.1371/journal.pmed.0030353.g003
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sampling of specimens for PCR analysis was accounted for in
the analysis which based on weighted averages. A p-value of
less than 0.05 (two-tailed) was considered signiﬁcant. Stata/SE
8.0 (Stata Corporation, College Station, Texas, United States)
was used for the analysis.
Ethics and Informed Consent
After the project’s purpose was explained, patients—or in
the case of minors, their parents or guardians—gave verbal
consent prior to participation in the study. Participation
consisted of providing faecal specimens and the information
required to complete the case report forms. All studies were
approved by each site’s local ethics review committees.
International approval for all studies, except the study in
Bangladesh, was obtained from the Secretariat Committee for
Research Involving Human Subjects, WHO, Geneva, Switzer-
land. The study in Bangladesh was approved by the
Bangladeshi Government and by the ICDDR,B ethics review
board, which has international membership.
Results
In the six sites, a total of 605,331 people were studied
between 1 and 3 years, resulting in 1,415,583 person-years of
shigellosis surveillance (Table 1). The project detected 62,266
diarrhoea episodes, of which 56,958 (91%) fulﬁlled the
eligibility criteria, which consisted of diarrhoea for 1 d or
more and patient consent to participate in the study (Figure 1).
Incidence
The overall diarrhoea incidence was 40 episodes per 1,000
patients per year in all age groups and 254/1,000/y among
those under age 60 mo. Shigella was isolated from 2,927/56,958
(5%) of diarrhoea episodes. The overall incidence of treated
shigellosis was 2.1 episodes/1,000/y in all ages and 13.2/1,000/y
in children under age 60 mo. The shigellosis incidence
increased after age 40 y (test for trend, p , 0.001; Figure 2).
The shigellosis rates of the overall population as well as in
children under 5 y in the site in Bangladesh were statistically
signiﬁcantly higher than the shigellosis rates in China,
Pakistan, and Indonesia (p , 0.001), which in turn were
signiﬁcantly higher than those in the two countries with the
lowest shigellosis rates, Vietnam and Thailand (p , 0.001;
Table 1).
Clinical Presentations of Shigellosis Episodes
Culture-conﬁrmed shigellosis cases frequently reported
more than one clinical sign or symptom, ranging from watery
stools through mucoid stools to dysentery. During 1,807
(65%) of 2,766 culture-conﬁrmed shigellosis episodes, watery
diarrhoea was reported; in 1,518 (54%) of 2,802 episodes
patients reported mucoid stools; and 790 (27%) of 2,925
episodes patients reported dysentery (Figure 3). In multiple
logistic regression models adjusted for study site and age of
the patient four clinical signs and symptoms correlated
positively with the detection of Shigella spp in stool speci-
mens: dysentery, mucoid diarrhoea, fever, and abdominal
cramps (Table 2). In contrast, watery diarrhoea and vomiting
were signiﬁcantly more frequently reported during diarrhoea
episodes from which no Shigella spp. was isolated. The
percentage of shigellosis patients admitted for hospital care
varied between the sites. None of 394 shigellosis patients in
Pakistan was admitted, in contrast to 71 of 390 (18%)
shigellosis cases in Vietnam (Table 1).
Differences in the Age of Shigellosis Patients between
Study Sites
The median age of shigellosis patients in Bangladesh and
Pakistan was 2 y; in Vietnam was 4 y; and in Indonesia and
Thailand 5 y. China was a outlier with a median age of 32 y
(Kruskal-Wallis test; 5 degrees of freedom; p, 0.001). By age 2
y, 37% and 38% of shigellosis patients in Bangladesh and
Pakistan, respectively, had acquired the infection; in Indo-
nesia and Vietnam 30% and 28%, respectively; in Thailand
12%; and in China 5% (Chi-square test; 5 degrees of freedom;
p , 0.001).
Outcome of Shigellosis Episodes
Of 1,114 eligible shigellosis patients, 870 (18%) were
followed for 14 d or longer, and 845 (76%) were followed
for 90 d in the study sites in China, Vietnam, and Pakistan. Of
the 870 (18%) shigellosis patients who were followed for at
least 14 d, 153 (18%) reported that the total diarrhoea episode
lasted for 14 d ormore (Table 3); 91 (11%) stated that diarrhoea
was still present 14 d after presentation. Of 845 patients with
culture-conﬁrmed shigellosis, 21 (3%) reportedmedical events
such as pneumonia during the 90d follow-upperiod.Nodeaths
were detected following shigellosis episodes. Five clinical signs
and symptoms at the time of presentation were statistically
Table 3. Persistent Diarrhoea and Other Sequelae of 870 Shigellosis Episodes in China, Vietnam, and Pakistan
Symptoms Study Country China Vietnam Pakistan Total
Persistent diarrhoea Patients followed for 14 d 304 205 361 870
Patients with diarrhoea more than a total of 14 da
(% of patients followed for 14 d)
27 (9%) 20 (10%) 106 (29%) 153 (18%)
Patients with diarrhoea for 14 d or more after presentation
(% of patients followed for 14 d)
3 (1%) 16 (8%) 72 (20%) 91 (11%)
Sequelae within 90 d
of presentation
Patients followed for 90 d 300 202 343 845
Pneumonia episodes 1 2 12 15
Other complaintsb 3 0 3 6
Deaths 0 0 0 0
aIncluding days of diarrhoea prior to presentation.
bGastroenteritis (n¼ 3), accident with head trauma (n¼ 1), heart disease (n¼ 1), no diagnosis (n¼ 1).
DOI: 10.1371/journal.pmed.0030353.t003
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signiﬁcantly associated with persistent diarrhoea in adjusted
regression models age, fever, mucoid diarrhoea, vomiting, and
abdominal cramps (Table 4). No statistically signiﬁcant
association was detected between Shigella species, antimicro-
bial resistance, and persistent diarrhoea.
Microbiology
S. ﬂexneri was the most frequently isolated species (1,976
[68%] of 2,927) at all sites except in Thailand, where S. sonnei
was most common (124 [85%] of 146; p , 0.001; Figure 4). S.
boydii was infrequently isolated, except in Bangladesh where it
was the second most-common species, accounting for 23%
(106 of 464) of shigellosis episodes. In all, 110 (4%) S.
dysenteriae serotypes were isolated but none was S. dysenteriae
type 1. In each of the six study sites S. ﬂexneri was signiﬁcantly
more frequently isolated from patients ages 60 mo or older
than from children under age 60 mo (Figure 4, left bar graph;
p , 0.0001). In contrast, S. sonnei was more frequently isolated
from children under age 60 mo than from patients age 60 mo
or older (Figure 4, right bar graph; p, 0.0001). Dysentery and
cramps were signiﬁcantly more frequently reported by
patients with diarrhoea from whom S. ﬂexneri was isolated
(Table 5).
The eight most frequently isolated S. ﬂexneri serotypes (in
order of prevalence 2a, 3a, 1a, 1b, 2b, 1c, 6, x) were
responsible for 90% of all S. ﬂexneri episodes in all ﬁve study
sites where S. ﬂexneri is the dominant Shigella species (Table 6).
There were statistically signiﬁcant differences in serotype
prevalence of S. ﬂexneri isolates between study sites (Chi
square; 40 degrees of freedom; p , 0.001).
In Indonesia, Bangladesh, and Pakistan the S. ﬂexneri
serotype distribution was compared from one year to the
next and in Thailand and Vietnam over 3 y. Statistically
signiﬁcant shifts in the in the relative proportions of S. ﬂexneri
serotypes were seen in each site (p, 0.001), with the exception
of the site in Thailand, where over a 3 y period only 22 S.
ﬂexneri strains were isolated and no statistically signiﬁcant
shifts in the distribution of serotypes were observed.
Antimicrobial Resistance
A high percentage of Shigella strains were resistant to
ampicillin and cotrimoxazole at all sites (Table 7). The highest
percentage of ampicillin-resistant isolates was found in S.
ﬂexneri (84%), followed by S. dysenteriae (37%), S. boydii (25%),
and S. sonnei (10%; p , 0.001). In contrast, the highest
percentage of cotrimoxazole-resistant specimens were S.
sonnei (92%), followed by S. ﬂexneri (76%), S. dysenteriae
(62%), and S. boydii (49%; p , 0.001). Resistance to nalidixic
acid varied widely, from 100% of S. ﬂexneri and 98% of S.
sonnei in China, through 75% of S. sonnei and 48% of S. ﬂexneri
in Bangladesh, to little or no resistance at the other sites.
Ciproﬂoxacin-resistant S. ﬂexneri isolates were identiﬁed in
China (18 [6%] of 305), Pakistan (8 [3%] of 242), and Vietnam
(5 [2%] of 282). Of the 1,653 ampicillin-resistant and the 1,490
cotrimoxazole-resistant S. ﬂexneri isolates, 1,322 were cross-
resistant to ampicillin and cotrimoxazole. Eighteen isolates
were resistant to all four tested antimicrobials.
Detection of ipaH using Real-Time PCR
Of 427 Shigella culture-positive specimens, ipaH was
detected in 385 (90%). In 1,124 culture-negative patients
who reported dysentery, 564 (50%) had ipaH in the stool, in
contrast to 673 of 1767 (38%) patients with nonbloody
diarrhoea (p ¼ 0.0001). The highest percentage of culture-
negative, ipaH-positive specimens was detected in the two
countries with the highest shigellosis incidence, China (52%;
95% CI, 45%–60%), and Bangladesh (45%; 95% CI, 42%–
49%). In Thailand, one of the sites with the lowest shigellosis
incidence rate, ipaH was detected in 14% (95% CI, 9%–19%)
of stool samples (Table 1). In Vietnam, another country with
relatively low shigellosis incidence, ipaH was detected in 38%
(95% CI, 32%–43%) of stool samples.
Figure 4. The Relative Distribution of S. flexneri and S. sonnei at Study Sites in Six Asian Countries
S. flexneri (left bar graph) was more frequently isolated from diarrhea patients 5 y and older (p , 0.0001). In contrast, S. sonnei (right bar graph) was
more frequently isolated from children under 5 y of age (p , 0.0001).
DOI: 10.1371/journal.pmed.0030353.g004
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IpaH detection was lowest in children under age 6 mo,
peaked between the second and tenth year of life, after which
the percentage of ipaH-positive specimens declined until age
40 y, at which time the percentage of positive specimens
increased again (Figure 5). Due to the semiquantitative nature
of real-time PCR it is possible to compare the relative
bacterial load between age groups, which is inversely related
to the number of cycles required to detect ipaH (Figure 5).
The bacterial load was relatively low during the ﬁrst year of
life and peaked during the second year of life. Between 5 and
40 years of life the bacterial load was relatively low, but it
increased again after age 40 y.
Table 6. The S. flexneri Serotype Distribution in Six Study Sites
S. flexneri
Serotypes
Indonesia (% of
Total Serotypes)
Vietnam (% of
Total Serotypes)
China (% of
Total Serotypes)
Thailand(% of
Total Serotypes)
Pakistan (% of
Total Serotypes)
Bangladesh (% of
Total Serotypes)
All Countries (% of
Total Serotypes)
1a 63 (7%) 1 (0%) 104 (34%) 0 (0%) 5 (2%) 0 (0%) 173 (9%)
1b 105 (12%) 7 (2%) 0 (0%) 5 (23%) 25 (10%) 29 (11%) 171 (9%)
1c 103 (12%) 0 (0%) 0 (0%) 0 (0%) 4 (2%) 26 (10%) 133 (7%)
2a 297 (34%) 69 (24%) 84 (28%) 8 (36%) 38 (16%) 69 (27%) 565 (29%)
2b 5 (1%) 103 (37%) 1 (0%) 0 (0%) 23 (10%) 17 (7%) 149 (8%)
3a 142 (16%) 58 (21%) 1 (0%) 1 (5%) 9 (4%) 62 (24%) 273 (14%)
3b 10 (1%) 3 (1%) 0 (0%) 5 (23%) 1 (0%) 1 (0%) 20 (1%)
3c 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (1%) 0 (0%) 3 (0%)
4 12 (1%) 11 (4%) 7 (2%) 0 (0%) 12 (5%) 8 (3%) 50 (3%)
4a 53 (6%) 4 (1%) 0 (0%) 1 (5%) 18 (7%) 2 (1%) 78 (4%)
4b 1 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (1%) 0 (0%) 3 (0%)
4x 11 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (1%) 14 (1%)
5a 2 (0%) 0 (0%) 1 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (0%)
6 38 (4%) 12 (4%) 0 (0%) 0 (0%) 37 (15%) 28 (11%) 115 (6%)
x 2 (0%) 0 (0%) 100 (33%) 0 (0%) 1 (0%) 0 (0%) 103 (5%)
y 5 (1%) 2 (1%) 5 (2%) 0 (0%) 0 (0%) 3 (1%) 15 (1%)
Not typed 17 (2%) 12 (4%) 2 (0%) 2 (9%) 64 (26%) 11 (4%) 108 (5%)
Total 866 (100%) 282 (100%) 305 (100%) 22 (100%) 242 (100%) 259 (100%) 1,976 (100%)
DOI: 10.1371/journal.pmed.0030353.t006
Table 5. Clinical Presentationa of Each Shigella spp. Compared with All Other Shigella spp. Isolated
Symptom Species Total
Assayed
Symptom
Present (%)
Symptom
Absent (%)
Crude
OR
95% CI Adjusted
ORb
95% CI p-Value
Dysentery S. flexneri 1,974 588 (30%) 1,386 (70%) 1.57 1.31–1.89 1.66 1.36–2.02 ,0.001
Shigella spp. other than S. flexneri 951 202 (21%) 749 (79%)
S. sonnei 652 145 (22%) 507 (78%) 0.72 0.59–0.89 0.71 0.57–0.90 0.004
Shigella spp. other than S. sonnei 2,273 645 (28%) 1,628 (72%)
S. boydii 189 42 (22%) 147 (78%) 0.76 0.53–1.08 0.71 0.49–1.03 0.07
Shigella spp. other than S. boydii 2,736 748 (27%) 1,988 (73%)
S. dysenteriae 110 15 (14%) 95 (86%) 0.41 0.23–0.72 0.37 0.21–0.64 ,0.001
Shigella spp. other than S. dysenteriae 2,815 775 (28%) 2,040 (72%)
Mucoid
diarrhoea
S. flexneri 1,874 1,022 (55%) 852 (45%) 1.05 0.89–1.22 1.10 0.92–1.32 0.3
Shigella spp. other than S. flexneri 928 496 (54%) 432 (46%)
S. sonnei 630 351 (56%) 279 (44%) 1.08 0.91–1.30 1.11 0.91–1.37 0.3
Shigella spp. other than S. sonnei 2,172 1,167 (54%) 1,005 (46%)
S. boydii 188 98 (52%) 90 (48%) 0.92 0.68–1.23 0.72 0.52–1.02 0.06
Shigella spp. other than S. boydii 2,614 1,420 (54%) 1,194 (46%)
S. dysenteriae 110 47 (43%) 63 (57%) 0.62 0.42–0.91 0.60 0.40–0.92 0.02
Shigella spp. other than S. dysenteriae 2,692 1,471 (55%) 1,221 (45%)
Cramps S. flexneri 1,844 330 (18%) 1,514 (82%) 1.17 0.93–1.47 1.32 1.00–1.73 0.05
Shigella spp. other than S. flexneri 803 126 (16%) 677 (84%)
S. sonnei 506 49 (10%) 457 (90%) 0.46 0.33–0.63 0.91 0.64–1.31 0.6
Shigella spp. other than S. sonnei 2,141 407 (19%) 1,734 (81%)
S. boydii 188 58 (31%) 130 (69%) 2.31 1.67–3.21 0.88 0.60–1.29 0.5
Shigella spp. other than S. boydii 2,459 398 (16%) 2,061 (84%)
S. dysenteriae 109 19 (17%) 90 (83%) 1.02 0.61–1.68 0.49 0.28–0.87 0.01
Shigella spp. other than S. dysenteriae 2,538 437 (17%) 2,101 (83%)
aFour symptoms (fever, watery diarrhoea, vomiting, and seizures) have been omitted from this table because there were no statistically significant differences between the four Shigella spp.
bAdjusted for age and for site.
DOI: 10.1371/journal.pmed.0030353.t005
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Discussion
This ﬁrst multicentre shigellosis surveillance study found
that shigellosis is more ubiquitous than previously thought.
At six Asian study sites the overall culture-conﬁrmed
shigellosis annual incidence was 13.2 per 1,000 children
under age 5 y and 2.1/1,000 in all ages. The shigellosis
incidence in the study sites is approximately 100-fold higher
than in industrialized countries. In the US in 1999 and the
Netherlands 1996–2000 the estimated incidence shigellosis
incidence in all ages was 3.7 and 3.2, respectively, per 100,000
per year [35,36]. Shigellosis incidence at our Asian study sites
is in the same range as in Chile, where Prado and coworkers
reported 9.0–12.6 shigellosis episodes per 100 children aged
12–47 mo in a semirural area between 1994 and 98 [37].
Although considerable shigellosis burden was detected, the
actual burden caused by shigellosis was underestimated for
two reasons. First, in using passive surveillance for case
detection, we depended on the healthcare-seeking behaviour
of individual patients. Studies of the care-seeking behaviour
conducted in the context of the shigellosis surveillance
studies in each site found signiﬁcant differences in treatment
uptake for diarrhoea and dysentery not only between sites
but also within sites between adults and children and between
patients presenting with diarrhoea and dysentery [15–20].
Shigellosis patients who treated themselves or sought health-
care from providers outside the surveillance system could not
be captured. Active surveillance would have provided a more
complete detection of all diarrhoea episodes at the risk of
capturing trivial episodes that do not require medical care.
Data collected in the mid-1980s in a poor, periurban
community in Santiago, Chile, indicated that among children
under one year of age, 88% of episodes of diarrhoea were
mild cases that did not require health care but were detected
by active household surveillance [13]. Studies using alter-
native designs such as active case detection could provide a
more complete understanding of the shigellosis burden in the
study sites.
Second, Shigella spp. are highly fastidious organisms that
die rapidly in an unsuitable environment, including the
unavoidable temperature ﬂuctuations encountered during
transport. Therefore a sample of culture-negative stool
Table 7. Antimicrobial Resistance Pattern for Four Shigella Species
Antibiotic S. flexneri Serotypes (% of n) S. boydii (% of n) S. dysenteriae (% of n) S. sonnei (% of n)
2a (n ¼ 527) Other (n ¼ 1,449) Total (n ¼ 1,976) (n ¼ 189) (n ¼ 110) (n ¼ 652)
Ampicillin 497 (94.3%) 1,156 (79.8%) 1,653 (83.7%) 46 (24.3%) 41 (37.3%) 64 (9.8%)
Cotrimoxazole 423 (80.3%) 1,067 (73.6%) 1,490 (75.4%) 91 (48.2%) 68 (61.8%) 603 (92.5%)
Nalidixic acid 172 (32.6%) 301 (20.7%) 473 (23.9%) 40 (21.2%) 9 (8.2%) 92 (14.1%)
Ciprofloxacin 11 (2.1%) 20 (1.4%) 31 (1.6%) 2 (1.1%) 0 (0%) 1 (0.2%)
Multidrug-resistanta 8 (1.5%) 10 (0.7%) 18 (0.9%) 0 (0%) 0 (0%) 0 (0%)
aIsolates are resistant to ampicillin, cotrimoxazole, nalidixic acid, and ciprofloxacin.
DOI: 10.1371/journal.pmed.0030353.t007
Figure 5. Relation of Proportion of ipaH-Positive Faecal Specimens and PCR Cycle Number to Age
The percentage of Shigella culture-negative stool specimens from diarrhea patients in which ipaH was detected and the mean PCR cycle number
required to detect ipaH by patient age suggests that children between ages 2 and 4 y and adults over age 40 y with diarrhoea are most likely to have
ipaH in their stool specimens and the bacterial load is likely to be highest in these two age groups.
DOI: 10.1371/journal.pmed.0030353.g005
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specimens from each site was subjected to PCR analysis,
which has been found to highly sensitive and speciﬁc for
Shigella spp. in Asia [33]. Evidence of Shigella DNA was
detected in one-third of culture-negative stool specimens.
The proportion of PCR-positive stool specimens correlated
with age groups, thus lending support to the PCR ﬁndings.
Presently it is unknown whether the detection of genetic
material related to Shigella indicates disease, colonisation, or
asymptomatic carriage. The percentage of PCR-positive
specimens should therefore be viewed as upper limits of
diarrhoeal disease potentially caused by Shigella spp.
Besides these limitations we found two additional explan-
ations for earlier underestimates of the shigellosis burden.
We found that less than one-third of culture-proven
shigellosis episodes presented with dysentery. Clinical case
deﬁnitions that include only patients with a history of
dysentery, frequently used in government data collections,
miss more than two-thirds of shigellosis cases. Lastly, in
contrast to many other enteric infections, shigellosis is clearly
not conﬁned to childhood. On the contrary, the incidence of
shigellosis not only increased steadily after age 40 y, but the
bacterial load of shigellosis patients increased after age 40 y,
suggesting that older people as well as very young children
shed the highest bacterial load and may contribute dispro-
portionally to the transmission of shigellosis. Based on these
observations, we hypothesize that shigellosis is responsible for
a larger proportion of the diarrhea burden in Asia than was
previously inferred from culture results or clinical diagnoses.
Equally surprising was the benign clinical course of the
shigellosis episodes. No deaths were detected and only 21/845
(3%) of patients reported medical events during follow-up.
Persistent diarrhea was seen in 18% of patients following
shigellosis episodes; however, the clinical importance of these
persistent episodes is not clear. Earlier reports from the Asian
region have stressed the potential severity and poor outcome
of shigellosis episodes [38–40]. Several explanations for the
unexpectedly low morbidity and mortality following shigel-
losis have been considered. First, by consenting to participate
in the study, patients were assured to receive adequate
treatment. Second, the Shigella strains may have changed
during the decade since earlier reports on high shigellosis
morbidity and mortality appeared. The absence of S.
dysenteriae type 1, the only Shigella species with chromosomal
genes encoding the 70-kDa heterodimeric protein known as
Shiga toxin, supports this suggestion [41]. Third, earlier
studies reporting high morbidity and mortality were hospital-
based. As only the most severe shigellosis cases are admitted,
the study population is likely to differ from outpatients
enrolled in our study. Overall in our study, 6% of shigellosis
patients were admitted, with large differences in hospital-
ization rates between sites. The range of hospitalization rates
is perhaps best explained by differences in hospitalization
policies between countries; for example, Vietnam has a very
low threshold for triggering admissions compared to Paki-
stan. Finally, the host characteristics have changed over the
last decade. While severe malnutrition in childhood remains a
problem in the region, the prevalence of malnutrition has
declined over the last ten years with the steady increase of
economic markers. The widespread increase in income has
contributed to the easy access to antibiotics in each of the
study sites. In general, patients may have become less
vulnerable to severe disease due to the availability of better
nutrition and early self-treatment with antibiotics.
The over-the-counter sale of antibiotics without prescrip-
tion enjoys popularity in all our study sites and may be
responsible for the emergence of antibiotic resistance. The
project conﬁrmed that ampicillin and cotrimoxazole no
longer have a place in the treatment of shigellosis. Nalidixic
acid was recommended by the WHO as the ﬁrst-line treat-
ment against shigellosis until 2004, when it was replaced by
ciproﬂoxacin [42]. Complete resistance to nalidixic acid in
China and high levels of resistance in Bangladesh have clearly
reduced the usefulness of this drug, at least in these two
countries. Already 6% of S. ﬂexneri isolates in China are
resistant to ciproﬂoxacin. The emergence of multidrug-
resistant Shigella isolates could reverse the benign course of
shigellosis episodes observed in this study.
The prevention of shigellosis could exert an immediate
beneﬁt by substantially reducing the diarrhea burden in the
region and by preventing the spread of panresistant Shigella
strains. Safe water supplies and adequate sanitation com-
bined with improved hygiene are likely to reduce the
shigellosis burden in the future. Steady economic growth is
likely to overcome the barriers currently obstructing im-
provements in infrastructure for underserved populations.
But such progress can take decades and will provide little
relief to unstable and mobile populations. In this context a
safe and affordable vaccine to protect against shigellosis
would be a welcome public health tool. Several Shigella
vaccine candidates are under development [5–10]. Our
ﬁndings indicate that vaccines to prevent shigellosis may
need to be tailored according to prevalent species and
serotypes, since only type-speciﬁc immunity has been
demonstrated in humans [11–13] and cross-serotype protec-
tion is controversial [14].
We found an unexpectedly complex landscape of circulat-
ing Shigella strains in six Asian countries. The Shigella species
believed to be dominant are S. ﬂexneri in resource-poor
countries and S. sonnei in industrialized nations. Consistent
with previous reports [1], S. ﬂexneri was most frequently
isolated in the study sites in the ﬁve resource-poor countries
(Bangladesh, China, Pakistan, Indonesia, and Vietnam),
whereas in Thailand, which is rapidly becoming industrial-
ized, S. sonnei was the most common species. Surprisingly, S.
boydii, which had been thought to be relatively rare, was
responsible for nearly one-quarter of shigellosis episodes at
the Bangladesh site. Relatively few S. dysenteriae were detected
during this surveillance project. Amongst the S. ﬂexneri
isolates were a surprisingly wide range of serotypes that
varied across the Asian sites. The large variety in Shigella
species and serotypes may explain the unusual age distribu-
tion of this enteric disease: Patients may remain susceptible
to serotypes to which they have not been exposed earlier. The
ﬁnding that S. sonnei is more frequently isolated in younger
than in older children and S. ﬂexneri is more frequently
isolated from older than from younger shigellosis patients
may be evidence for the steady replacement of Shigella strains
with increasing age.
Not only do S. ﬂexneri serotypes vary geographically, they
vary temporally. We found statistically signiﬁcant shifts in S.
ﬂexneri serotypes between observation years at each of the
three sites where a comparison was possible. Temporal shifts
in Shigella serotypes have been reported previously in Kolkata,
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India [43] but not in Santiago, Chile, where the serotype
distribution was stable over prolonged periods [13]. Such
shifts pose a double challenge for vaccine developers, who
must choose the most relevant serotypes for inclusion in a
multivalent vaccine, while knowing that replacement strains
may emerge following the widespread introduction of the
vaccine. To have a major epidemiological impact a shigellosis
vaccine may need be a cocktail of antigens from several
Shigella species and serotypes. An alternative approach would
be to search for an antigen common to all Shigella species and
serotypes. A vaccine that could elicit immunity against such a
common antigen may be a promising future strategy to
control shigellosis.
In conclusion, shigellosis is a frequent cause of diarrhea in
the more impoverished areas of Asia. Although there were few
medical complications associated with shigellosis, control of
this disease could reduce of the overall diarrhea burden
globally. The development of a vaccine protective against
shigellosis is a highly desirable public health goal, but the
development of such a vaccine is complicated by the variation
in species and serogroups between sites, years, and age groups.
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Editors’ Summary
Background. Infections that cause diarrhea are a major public health
problem in developing countries and other places where resources are
scarce, particularly in young children. Although deaths from diarrhea
have decreased considerably in recent decades, diarrheal illnesses
continue to cause some 2.5 million deaths each year. Shigella, a group
of rod-shaped bacteria closely related to those that normally live in the
human intestine, is known to cause severe diarrhea in both developed
and developing countries, but the global impact of Shigella infection
(shigellosis) has not been well characterized. Shigella exists in more than
40 different varieties, an increasing number of cases have been found to
be resistant to available antibiotics, and no vaccine is licensed except
one oral vaccine in China.
Why Was This Study Done? The best information available on the
impact of shigellosis has been based on historical estimates, which are
subject to inaccuracy. More recent studies suggest that the older reports
may have underestimated the impact of shigellosis. The authors of this
study wanted to obtain more accurate, current estimates of the impact
of shigellosis in developing countries.
In addition, immunity to one type of Shigella does not necessarily
provide protection against other types. Therefore, in order to develop an
effective vaccine, researchers would need to know which types of
Shigella are causing illness in affected parts of the world. Accordingly, the
authors of this study also wanted to investigate the specific types of
Shigella (called ‘‘serotypes’’ because they can be distinguished using
serum from immune individuals) involved in cases of diarrhea.
What Did the Researchers Do and Find? The researchers set up
surveillance projects for diarrhea in six developing countries throughout
Asia: at three rural or semirural sites (in China, Vietnam, and Thailand)
and three urban slum sites (in Bangladesh, Pakistan, and Indonesia). They
conducted information campaigns in each area to encourage residents
to visit a participating clinic if they or their children developed diarrhea.
Patients presenting with diarrhea were enrolled in the study and their
medical findings were documented on standardized report forms. Stool
or rectal swab specimens were obtained (with patient consent) and sent
to laboratories to test for Shigella. When Shigella was identified, the
bacteria was serotyped and tested for resistance to antibiotics. Because
standard culture methods do not always detect Shigella when it is
present, as a double-check, the researchers also tested some of the
specimens for a type of DNA (called the ipaH gene) that serves as a
molecular ‘‘footprint’’ of Shigella. Patients received treatment according
to national guidelines.
The study involved approximately 600,000 participants over 1–3
years, and detected approximately 60,000 cases of diarrhea. Shigella was
found in 5% of diarrhea episodes, meaning that two new cases of
shigellosis occurred per 1,000 people (of all ages) per year. Rates were
higher in children and in people over age 40. Among children less than 5
years old, there were 13 new cases per 1,000 children per year. Rates of
shigellosis were higher in the Bangladesh site than in the China, Pakistan,
and Indonesia sites, which in turn had higher rates than the Vietnam and
Thailand sites.
In contrast to prior studies, no deaths were detected following
episodes of shigellosis, and less than one-third of cases of shigellosis
were associated with bloody diarrhea (dysentery).
The distribution of serotypes was found to differ from one site to
another and within a given site over time. A high percentage of Shigella
detected at all sites were resistant to two or more antibiotics. Testing for
the ipaH gene was able to identify Shigella in half of patients with bloody
diarrhea whose routine stool cultures did not reveal Shigella.
What Do These Findings Mean? This study found that shigellosis
occurs in these Asian sites at a rate approximately 100 times higher than
in industrialized countries. The finding that shigellosis frequently occurs
in the absence of bloody stool means that government data collections
using dysentery as part of the case definition can be expected to miss
the majority of shigellosis cases. Also, the increased rate of shigellosis
above age 40 shows that older people share significantly in the burden
(and most likely the transmission) of shigellosis.
The generally benign clinical course of Shigella-associated diarrhea
calls into question the priority that this disease should receive in global
vaccine development efforts, especially given the technological chal-
lenges posed by the complex and variable distribution of serotypes.
Nonetheless, the emergence of multidrug-resistant strains clearly
remains a threat, and raises the perennial issue of improved sanitation,
rather than new antibiotics, as a long-term solution to the plethora of
water-borne illnesses that disproportionately affect developing coun-
tries.
Additional Information Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030353.
 World Health Organization topic page on diarrhea
 Centers for Disease Control and Prevention: Shigellosis
 Wikipedia entry on Shigella (note: Wikipedia is a free Internet
encyclopedia that anyone can edit)
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